Co-Diagnostics, Inc. (CODX)
| Market Cap | 166.88M |
| Revenue (ttm) | 100.56M |
| Net Income (ttm) | 40.47M |
| Shares Out | 33.99M |
| EPS (ttm) | 1.23 |
| PE Ratio | 3.99 |
| Forward PE | 6.14 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 211,356 |
| Open | 5.01 |
| Previous Close | 5.03 |
| Day's Range | 4.88 - 5.09 |
| 52-Week Range | 3.66 - 11.82 |
| Beta | -1.54 |
| Analysts | Buy |
| Price Target | 19.72 (+301.6%) |
| Earnings Date | May 12, 2022 |
About CODX
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for ...
Financial Performance
In 2021, Co-Diagnostics's revenue was $97.89 million, an increase of 31.30% compared to the previous year's $74.55 million. Earnings were $36.66 million, a decrease of -13.70%.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for CODX stock is "Buy." The 12-month stock price forecast is 19.72, which is an increase of 301.63% from the latest price.
News
CoDiagnostics, Inc. (CODX) Q1 Earnings and Revenues Beat Estimates
CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 44.44% and 6.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Co-Diagnostics Reports Solid First Quarter 2022 Financial Results
Strong results highlighted by record first quarter revenue of $22.7 million and diluted EPS of $0.34 SALT LAKE CITY , May 12, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagn...
Co-Diagnostics, Inc. to Host Booth at Medical Fair Brasil 2022 in São Paulo on May 3-6
SALT LAKE CITY , May 3, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of mole...
CO-DIAGNOSTICS, INC. ANNOUNCES FIRST QUARTER 2022 EARNINGS RELEASE DATE AND WEBCAST
SALT LAKE CITY , April 28, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, a...
Why the Earnings Surprise Streak Could Continue for CoDiagnostics, Inc. (CODX)
CoDiagnostics, Inc. (CODX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Co-Diagnostics, Inc. to Host Booth at ECCMID 2022 in Lisbon, Portugal on April 23-26
SALT LAKE CITY , April 22, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of m...
Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Hepatitis C Viral Load Test
SALT LAKE CITY , April 19, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular dia...
Why Co-Diagnostics Stock Tumbled by Nearly 12% Today
The company released its 2021 earnings, and investors weren't happy with them despite profitability guidance that beat estimates.
CoDiagnostics, Inc. (CODX) Q4 Earnings Beat Estimates
CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 66.67% and 5.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Co-Diagnostics Stock Is Trading Higher After Hours
Co-Diagnostics Inc (NASDAQ: CODX) shares are trading higher in Thursday's after-hours session after the company reported financial results and issued earnings guidance. Co-Diagnostics reported full year...
Co-Diagnostics Reports Full Year 2021 Financial Results
Achieved Record Full Year Revenue of $97.9 Million; Strength in Sales Momentum Provides Foundation to Achieve Solid FY'22 SALT LAKE CITY , March 24, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CO...
Co-Diagnostics, Inc. to Present at MarketsandMarkets Conference on March 23-24 in London, England
SALT LAKE CITY , March 22, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular dia...
Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board
SALT LAKE CITY , March 17, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular dia...
CoDiagnostics, Inc. (CODX) Surges 13.1%: Is This an Indication of Further Gains?
CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price in...
Why Co-Diagnostics Is Soaring Today
The diagnostics and research outfit gave investors a dose of good news today.
Why Co-Diagnostics Shares Are Trading Higher Today
Co-Diagnostics Inc (NASDAQ: CODX) shares are trading higher Tuesday after the company announced its board authorized a share repurchase program, allowing Co-Diagnostics to repurchase up to $30 million o...
Co-Diagnostics, Inc. Announces Authorization of $30 Million Share Repurchase Program
SALT LAKE CITY , March 15, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular dia...
CO-DIAGNOSTICS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 EARNINGS RELEASE DATE AND WEBCAST
SALT LAKE CITY , March 14, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, a...
Co-Diagnostics, Inc. to Sponsor and Present at Molecular Med Tri-Con 2022
SALT LAKE CITY, Feb. 17, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagn...
Co-Diagnostics, Inc. to Host Booth at Life Sciences Day on the Hill on February 16 at the Utah State Capital
SALT LAKE CITY, Feb. 10, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagn...
Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Hepatitis B Viral Load Test
SALT LAKE CITY, Feb. 3, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagno...
Co-Diagnostics, Inc. to Host Booth at Medlab Middle East 2022 in Dubai on January 24-27
SALT LAKE CITY, Jan. 21, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagn...
Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for High-Risk HPV Multiplex Test
SALT LAKE CITY, Jan. 13, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagn...
Co-Diagnostics, Inc. to Participate in the H.C. Wainwright 2022 BioConnect Virtual Conference on January 10-13
SALT LAKE CITY, Jan. 10, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular di...
Has CoDiagnostics, Inc. (CODX) Outpaced Other Medical Stocks This Year?
Here is how CoDiagnostics, Inc. (CODX) and Cronos Group (CRON) have performed compared to their sector so far this year.